Principles of antiplatelet therapy

Textbook of Interventional Cardiovascular Pharmacology

Volumn , Issue , 2007, Pages 31-40

  Altman, Raul ^a   Scazziota, Alejandra ^a   de Lourdes Herrera, María ^a  

^a Centro de Trombosis de Buenos Aires   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856279021     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (48)

1. Gordon JL, Milner AJ. Blood platelets as multifunctional cells. In: Gordon JL, ed. Platelets in Biology and Pathology, ch. 1. New York: Elsevier/ North-Holland Biomedical Press, 1976:3-22.
2. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24:1015-1022.
3. Ramasamy I. Inherited bleeding disorders: disorders of platelet adhesion and aggregation. Crit rev Oncol Hematol 2004; 49: 1-35.
4. Zwaal R, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cell. Blood 1997; 89:1121-1132.
5. Jurk K, Kehrel, B. Reliability of platelet function tests and drug monitoring platelets: physiology and biochemistry. Semin Thromb Hemost 2005; 31:381-392.
6. Kuijpers MJ, Schulte V, Oury C, et al. Facilitating roles of murine platelet glycoprotein Ib and alphaIIb beta3 in phosphatidylserine exposure during vWF-collagen-induced thrombus formation. J Physiol 2004; 558:403-415.
7. Nieswandt B, Watson S. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102:449-461.
8. Schmitz G, Rothe G, Ruf A, et al. European Working Group on clinical cell analysis: consensus protocol for the flow cyometric characterisation of platelet function. Thromb Haemost 1998; 79:885-896.
9. Shattil S, Newman P. Integrins: dynamic scaffolds for adhesion and signalling in platelets. Blood 2004; 104:1606-1615.
10. Lahav J, Jurk K, Hess O, et al. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood 2002; 100:2472-2478.
11. Furie B, Furie BC, Flaumenhaft R. A journey with platelet Pselectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 2001; 86:214-221.
12. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta 3 integrin-dependent mechanism. Nat Med 2002; 8:247-252.
13. Freedman J. Molecular regulation of platelet dependent thrombosis. Circulation 2005; 112:2725-2734.
14. Brass LF. Thrombin and platelet activation. Chest 2003; 124:18s-25s.
15. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low- dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373-2383.
16. AC ADP receptor-mediated signalling by the antiplatelet drug Clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19:2007-2011.
17. Minami T, Sugiyama A, Wu SQ, et al. Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 2004; 24:41-53.
18. Ishihara H, Connolly AJ, Zeng D, et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386:502-506.
19. Luque A, Carpizo DR, Iruela-Arispe ML. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF 165. J Biol Chem 2003; 278: 23656-23665.
20. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407:258-264.
21. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002; 415:175-179.
22. Altman R, Scazziota A, Rouvier J, Gonzalez C. Effect of sodium arachidonate on thrombin generation through platelet activation-inhibitory effect of aspirin. Thromb Haemost 2000; 84:1109-1112.
23. Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 2003; 42:423-438.
24. Hemker HC, Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74:134-138.
25. Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998; 9(suppl 1):S15-S20.
26. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST- segment elevation acute coronary syndromes. JAMA 2005; 294:3108-3116.
27. Rainger GE, Buckley C, Simmons DL, Nash GB. Neutrophils rolling on immobilised platelets migrate into homotypic aggregates after activation. Thromb Haemost 1998; 79:1177-1183.
28. Eriksson EE. Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects. Curr Opin Lipidol 2004; 15:553-558.
29. Narizhneva NV, Razorenova OV, Podrez EA, et al. Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J 2005; 19:1158-1160.
30. Chavakis T, Santoso S, Clemetson KJ, et al. High molecular weight kininogen regulates platelet-leukocyte interactions by bridging Mac-1 and glycoprotein Ib. J Biol Chem 2003; 278:45375-45381.
31. Naik UP, Eckfeld K. Junctional adhesion molecule 1 (JAM-1). J Biol Regul Homeost Agents 2003; 17:341-347.
32. Chavakis T, Keiper T, Matz-Westphal R, et al. The junctional adhesion molecule-C promotes neutrophil transendothelia l migration in vitro and in vivo. J Biol Chem 2004; 279:55602-55608.
33. Baltus T, von Hundelshausen P, Mause SF, Buhre W, Rossaint R, Weber C. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol 2005; 78:435-441.
34. Buchner K, Henn V, Grafe M, de Boer OJ, Becker AE, Kroczek RA. CD40 ligand is selectively expressed on CD4+ T cells and platelets: implications for CD40-CD40L signalling in atherosclerosis. J Pathol 2003; 201:288-295.
35. Heeschen C, Dimmeler S, Hamm CW, et al. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348:1104-1111.
36. Ba XQ, Chen CX, Xu T, Cui LL, Gao YG, Zeng XL. Engagement of PSGL-1 upregulates CSF-1 transcription via a mechanism that may involve Syk. Cell Immunol 2005; 237:1-6.
37. Ahn KC, Jun AJ, Pawar P, et al. Preferential binding of platelets to monocytes over neutrophils under flow. Biochem Biophys Res Commun 2005; 329:345-355.
38. Coughlin R, Camerer E. Participation in inflammation. J Clin Invest 2003; 111:25-27.
39. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A 1994; 91:8767-8771.
40. DwyerJ H, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxy- genase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004; 350:29-37.
41. Coffey MJ, Jarvis GE, Gibbins JM, et al. Platelet 12-lipoxygenase activation via glycoprotein VI. Involvement of multiple signaling pathways in agonist control of H(P)ETE synthesis. Circ Res 2004; 94:1598-1605.
42. Powell WS, Rokach J. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog Lipid Res 2005; 44:154-183.
43. Lotzer K, Spanbroek R, Hildner M, et al. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 2003; 23:E32-E36.
44. Judge HM, Buckland RJ, Holgate CE, Storey RF. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses. Platelets 2005; 16: 398-407.
45. Altman R, Luciardi HL, Muntaner J, Herrera RN. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J 2004; 2:1.
46. Altman R, Luciardi HL, Muntaner J, et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation 2002; 106: 191-195.
47. Jones SC. Relative thromboembolic risks associated with COX- 2 inhibitors. Ann Pharmacother 2005; 39:1249-1259.
48. Grosser T, Fries S, Fitzgerald AG. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116:4-15.